948.2000 -11.25 (-1.17%)
NSE Nov 07, 2025 15:31 PM
Volume: 305.5K
 

948.20
-1.17%
Sharekhan
Q2FY25 revenues totaling Rs. 1,201 crore, demonstrating a significant y-o-y growth rate of 20%.EBITDA stood at Rs. 236 crore, marking a remarkable y-o-y increase of 31%.
Strides Pharma Science Ltd. has gained 49.26% in the last 6 Months
More from Strides Pharma Science Ltd.
Recommended